CLNN(CLNN)
CLNN
ANALYST COVERAGE7 analysts
BUY
▲ +646.3%upside to target
Key MetricsTTM
Market Cap$68.96M
Revenue TTM$134.0K
Net Income TTM-$33.51M
Free Cash Flow-$18.10M
Gross Margin—
Operating Margin—
Net Margin—
Return on Equity233.9%
Return on Assets—
Debt / Equity-1.17
Current Ratio1.94
EPS TTM$-2.88
PRICE
Prev Close
6.81
Open
6.85
Day Range6.65 – 6.90
6.65
6.90
52W Range2.28 – 13.50
2.28
13.50
39% of range
VOLUME & SIZE
Avg Volume
487.1K
FUNDAMENTALS
P/E Ratio
-2.1x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
0.97
Market-like
TECHNICAL
RSI (14)
55
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 131 days
Sep 30
CLNN News
About
Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland.
Robert EtheringtonChief Executive Officer, President & Director
Benjamin GreenbergHead of Medical
Jerry MiragliaGeneral Counsel & Corporate Secretary
Mark G. MortensonChief Science Officer
Michael T. HotchkinChief Development Officer
Morgan R. BrownChief Financial Officer
Mary Anne McneilHead of Human Resources